Dr. Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences discusses uterine fibroids and the recent FDA approval of MYFEMBREE® for the treatment of heavy menstrual bleeding associated with uterine fibroids. MYFEMBREE is also being studied in endometriosis.
Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences. Dr. Arjona Ferreira was previously Senior Vice President, Clinical Development at Shionogi. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company’s U.S. Clinical Development organization and he served on the company’s U.S. Senior Leadership Team and the Global Scientific Committee. Prior to joining Shionogi, Dr. Arjona Ferreira spent over a decade at Merck & Co. where he was Executive Director of Clinical Research in Women’s Health. At Merck, he chaired the product development teams for all programs in contraception and women’s health. Dr. Arjona Ferreira earned his MD and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.